Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuanfei Baidu granules for hospitalized acute exacerbation of COPD
ISRCTN83930526Phase 3Completed
- Sponsor
- Tianjin Binhai New Area Dagang Hospital
- Start
- May 2024
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Xuanfei Baidu in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Tianjin Binhai New Area Dagang Hospital. Primary endpoint: Time to clinical symptom recovery. Started May 2024; status: completed.
02
Drugs
Xuanfei Baidu
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ISRCTN83930526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN83930526.